IRVINE, Calif., Dec. 16, 2011 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries today announced the successful completion of enrollment in the first human clinical study of its proprietary pTeroPure.
The purpose of the randomized, double-blind placebo-controlled study is to evaluate whether pTeroPure will lower cholesterol and blood pressure, as well as improve markers for oxidative stress in patients with dyslipidemia-meeting inclusion criteria. Investigators are also evaluating the safety of pTeroPure in these patients.pTeroPure is ChromaDex's proprietary brand of its patent-pending pterostilbene, a central ingredient in its recently launched BluScience ™ line of dietary supplements, now available at GNC. Pterostilbene is one of several stilbenes found in blueberries and other berries that have demonstrated pre-clinical benefits in a number of health factors including improved levels of cholesterol, blood pressure and oxidative stress. ChromaDex holds exclusive worldwide rights to patents pending for pterostilbene for these and other health benefits based on technology licensed from the University of Mississippi, as well as through additional intellectual property developed by the company or in conjunction with leading research institutions. William Spengler, President of ChromaDex, said, "Now that trial enrollment is successfully completed, we anticipate release of the trial data in Q2 2012. This first human clinical study of pTeroPure will provide an important independent clinical assessment of what we believe is an enormous opportunity with this product. We anticipate that additional clinical studies involving pTeroPure and other compounds in our pipeline will be initiated in the coming months." pTeroPure was recently named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company Frost & Sullivan. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694. About ChromaDex ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure pterostilbene for which it has worldwide, exclusive patent rights. ChromaDex Forward-Looking Statements: Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.